Winship Cancer Institute of Emory University | Strategic Alliance Partners

May 23, 2018

Suresh S. Ramalingam, MD, sheds light on the recent data with emerging agents in small cell lung cancer.

January 10, 2018

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses immunotherapy in Merkel cell carcinoma.

May 15, 2017

The National Cancer Institute has named Winship Cancer Institute at Emory University a Comprehensive Cancer Center.

March 23, 2017

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

March 09, 2017

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

March 08, 2017

Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.

March 02, 2017

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer at Winship Cancer Institute of Emory University, discusses recent advancements in the field of multiple myeloma.

December 21, 2016

Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), is quickly emerging as a therapeutic option for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who develop the acquired resistance mutation T790M.

November 23, 2016

Continuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.

August 17, 2016

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

May 09, 2016

Although advances have been made in imaging techniques for patients with glioblastoma multiforme, new tools are needed to supplement standard imaging sequences.

February 10, 2016

Suresh Ramalingam, MD, professor, Emory School of Medicine, and chief, Medical Oncology, Department of Hematology and Medical Oncology, Emory University, discusses combinations with immunotherapy agents and chemotherapy being investigated as potential treatments for patients with non–small cell lung cancer.

December 29, 2015

Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.

December 01, 2015

Suresh Ramalingam, MD, discusses the evolving role of checkpoint inhibitors in lung cancer and what challenges still remain.

October 29, 2015

Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?

September 29, 2015

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents.

August 28, 2015

New drug candidate necitumumab, which is being reviewed by the FDA as a treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, received a low cost-effectiveness evaluation in a study published in JAMA Oncology.

August 10, 2015

Walter J. Curran, Jr., MD, Executive Director, Winship Cancer Institute of Emory University, Associate Vice President, Woodruff Health Sciences Center, discusses new developments in the delivery of radiation for patients with lung cancer.

July 01, 2015

The landscape of therapeutic options for patients with myeloma at all phases of treatment has rapidly changed with the development of new drugs and targets.

June 09, 2015

Sagar Lonial, MD, discusses the future of monoclonal antibodies in multiple myeloma.